Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/19/2018 |
| Start Date: | March 15, 2017 |
| End Date: | August 2, 2018 |
To evaluate image quality of coronary CT angiography (cCTA) after sublingual and transdermal
administration of Nitroglycerin. Aim of this prospective research study is to investigate
equivalence on image quality after sublingual or transdermal Nitroglycerin administration
(H0).
Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.
administration of Nitroglycerin. Aim of this prospective research study is to investigate
equivalence on image quality after sublingual or transdermal Nitroglycerin administration
(H0).
Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.
Inclusion Criteria:
1. Scheduled cCTA with contrast.
2. Able to comprehend and sign the consent form.
Exclusion Criteria:
1. Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.
2. Acute circulatory failure associated with marked hypotension (shock).
3. Conditions associated with elevated intracranial pressure, cerebral haemorrhage and
head trauma.
4. Closed-angle glaucoma.
5. Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil
(Cialis), or vardenafil (Levitra) within the last 24 hours
6. Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)
7. Critical aortic stenosis
8. Systolic blood pressure < 90 mmHg
9. Pregnant or lactating female; premenopausal women with a positive urine pregnancy
test.
10. Age under 18
11. Unwilling or unable to inform consent.
We found this trial at
1
site
Click here to add this to my saved trials
